BRESAGEN
BresaGen is a developer of proteins and peptides, especially biogenerics. In October 2006, BresaGen was sold to Hospira Inc of the US, and Paragon made a 2.35x return on investment, and 135% IRR. Hospira acquired the company to further develop BresaGen’s intellectual property, and to distribute its products in the US.
BRESAGEN
Industry:
Biopharma Biotechnology
Address:
Thebarton, South Australia, Australia
Country:
Australia
Website Url:
http://www.bresagen.com.au
Status:
Closed
Contact:
+61882342660
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Wordpress Plugins Euro
Investors List
Paragon Private Equity
Paragon Private Equity investment in Private Equity Round - BresaGen
